Well, not so much
Why Researchers Study GHK-Cu
There are no trials of the amlodipine and valsartan combination tablet demonstrating reductions in cardiovascular risk in patients with hypertension, but the amlodipine component and several ARBs, which are the same pharmacological class as the valsartan component, have demonstrated such benefits
A number of studies were conducted but using intravenous or nebulized GSH
Lowering BP to target cuts the rate of loss of eGFR in half, and adding a RAASi, as done in the Irbesartan Diabetic Nephropathy Trial, further reduced this rate considerably (Table 4)
Living with Long COVID, ME/CFS, dysautonomia, or MCAS is a profoundly challenging experience that often requires navigating a medical system ill-equipped to handle complex, multi-systemic illnesses